S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in

Pressure BioSciences Stock Forecast, Price & News

+0.10 (+4.17 %)
(As of 02/24/2021 12:00 AM ET)
Today's Range
Now: $2.50
50-Day Range
MA: $2.38
52-Week Range
Now: $2.50
Volume14,957 shs
Average Volume19,265 shs
Market Capitalization$10.15 million
P/E RatioN/A
Dividend YieldN/A
Pressure BioSciences, Inc. develops pressure cycling technology (PCT) solutions in North America, Europe, and Asia. Its PCT technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations, including Barocycler 2320EXT, Barozyme-HT48, Barocycler HUB440, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as pressure used to lyse samples for extraction tubes and other processing tubes, as well as application specific kits, including consumable products and reagents. It serves government institutions, pharmaceutical and biotechnology companies, and academic laboratories. Pressure BioSciences, Inc. has a collaboration with The Steinbeis Centre for biopolymer analysis and biomedical mass spectrometry; and NutraLife Biosciences for the development of water-soluble Nanoemulsion-based nutraceuticals. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts.


Pressure BioSciences Ultra Shear Technology...
January 20, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry Analytical instruments
Current SymbolOTCMKTS:PBIO
Year FoundedN/A



Sales & Book Value

Annual Sales$1.81 million
Book Value($13.00) per share


Net Income$-11,660,000.00
Net Margins-1,158.98%


Market Cap$10.15 million
Next Earnings Date3/2/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

0.44 out of 5 stars

Medical Sector

1641st out of 1,958 stocks

Analytical Instruments Industry

27th out of 29 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.10 (+4.17 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for PBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Pressure BioSciences (OTCMKTS:PBIO) Frequently Asked Questions

What stocks does MarketBeat like better than Pressure BioSciences?

Wall Street analysts have given Pressure BioSciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pressure BioSciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Pressure BioSciences' next earnings date?

Pressure BioSciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Pressure BioSciences

How were Pressure BioSciences' earnings last quarter?

Pressure BioSciences, Inc. (OTCMKTS:PBIO) announced its earnings results on Tuesday, November, 17th. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($2.20) by $1.18. The company had revenue of $0.53 million for the quarter.
View Pressure BioSciences' earnings history

How has Pressure BioSciences' stock been impacted by COVID-19?

Pressure BioSciences' stock was trading at $2.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PBIO stock has increased by 25.0% and is now trading at $2.50.
View which stocks have been most impacted by COVID-19

Who are Pressure BioSciences' key executives?

Pressure BioSciences' management team includes the following people:
  • Mr. Richard T. Schumacher, Founder, Pres, CEO, Treasurer, Interim CFO, Clerk & Director (Age 71, Pay $320.37k)
  • Dr. Alexander V. Lazarev, Chief Science Officer (Age 56, Pay $207.31k)
  • Dr. Edmund Y. Ting Ph.D., Sc.D. Ph.D., Sr. VP of Engineering (Age 66, Pay $209.52k)

Who are some of Pressure BioSciences' key competitors?

What other stocks do shareholders of Pressure BioSciences own?

What is Pressure BioSciences' stock symbol?

Pressure BioSciences trades on the OTCMKTS under the ticker symbol "PBIO."

How do I buy shares of Pressure BioSciences?

Shares of PBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pressure BioSciences' stock price today?

One share of PBIO stock can currently be purchased for approximately $2.50.

How much money does Pressure BioSciences make?

Pressure BioSciences has a market capitalization of $10.15 million and generates $1.81 million in revenue each year.

How many employees does Pressure BioSciences have?

Pressure BioSciences employs 14 workers across the globe.

What is Pressure BioSciences' official website?

The official website for Pressure BioSciences is www.pressurebiosciences.com.

Where are Pressure BioSciences' headquarters?

Pressure BioSciences is headquartered at 14 NORFOLK AVENUE, SOUTH EASTON MA, 02375.

How can I contact Pressure BioSciences?

Pressure BioSciences' mailing address is 14 NORFOLK AVENUE, SOUTH EASTON MA, 02375. The company can be reached via phone at 508-230-1828 or via email at [email protected]

This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.